

Safety of intranasal human insulin: a review

Vera Schmid^{1,2,3}, Stephanie Kullmann^{1,2}, Wieland Gfrörer⁴, Verena Hund⁴, Manfred Hallschmid^{1,2,5}, Hans-Peter Lipp⁴, Hans-Ulrich Häring^{1,2,3}, Hubert Preissl^{1,2,3,6,7}, Andreas Fritsche^{1,2,3}, Martin Heni^{1,2,3}

1. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2. German Center for Diabetes Research (DZD e.V.), Tübingen, Germany
3. Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tübingen, Tübingen, Germany
4. University Pharmacy, University Hospital, Tübingen, Germany
5. Institute of Medical Psychology and Behavioral Neurobiology, Eberhard Karls University Tübingen, Tübingen, Germany
6. Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
7. Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tübingen, Tübingen, Germany

Corresponding author

Dr. Martin Heni
University Hospital Tübingen, Internal Medicine IV
Otfried-Müller-Str. 10
72076 Tübingen
Germany

E-mail: martin.heni@med.uni-tuebingen.de
Phone: +49 7071 2982714
Fax: +49 7071 292784

Abstract

Subheadings – aims

The nasal application of human insulin is frequently used for investigating brain insulin action. It is utilized in studies on the physiological role of insulin in the human brain as well as in therapeutic interventional trials and its effects have been investigated after both acute and long-term administration. This review aimed to assess the safety of intranasal human insulin in human studies and the temporal stability of nasal insulin sprays.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.13279

Material and Methods

The electronic search was performed using MEDLINE. We selected original research on intranasal human insulin without further additives in humans.

The studies included could be of any design as long as they used human intranasal insulin as their study product. All outcomes and adverse side effects were excerpted.

Results

Thirty-eight studies on 1092 persons with acute application and 18 studies on 832 persons with treatment lasting between 21 days and 9.7 years were identified. No cases of symptomatic hypoglycemia or severe adverse events were reported. Transient local side effects in the nasal area were frequently experienced after intranasal insulin and placebo spray, while other adverse events were less commonly reported. There are no reports of subjects who were excluded due to adverse events.

No instances of temporal stability of nasal insulin were reported in the literature. Tests on insulin that had been repacked into spray flasks revealed that it had a chemical stability of up to 57 days.

Conclusions

. Our retrospective review of published studies on intranasal insulin did not reveal any safety concerns. There is, however, insufficient data to ensure long-term safety of this modality of chronic insulin administration. Improved insulin preparations that cause less nasal irritation would be desirable for future treatment.

Introduction

Research in animals clearly demonstrates that the brain is an insulin-sensitive organ (1–3). Over the past few years, several studies have shown that the human brain is also insulin responsive (4,5). However, much of the experimental technology applied in animals obviously cannot be used in humans, since it is either too invasive or relies on genetic manipulation. One technique – the administration of insulin in the form of a nasal spray - has, nevertheless, proved to be particularly useful in studying insulin action in the human brain (6). Within minutes of spray application, the peptide hormone is detectable in the lumbar cerebrospinal fluid (CSF) in humans for at least 80 minutes (7). The pharmacokinetics of nasal human insulin spray were recently studied in 8-week-old mice (8). Following nasal application, labeled human insulin entered the brain within minutes and was detectable for more than 60 minutes in all investigated brain areas. Less than 3% of the administered insulin entered the circulation and no peripheral metabolic effects were detected up to 24 h post spray application. This study suggests that the transport of insulin into the brain after intranasal administration involves different mechanisms than the one found at the blood-brain barrier and may therefore enable to study the effects on the brain independent of the blood-brain barrier.

Early reports of the nasal administration using 40 U insulin in humans found no significant changes of circulating insulin levels (7,9), suggesting that intranasally applied insulin does not pass into the circulation. However, subsequent studies with higher insulin doses clearly demonstrated that small amounts of the nasally administered peptide pass into the bloodstream (10). Importantly, the amount of insulin absorbed is so small that no major changes in blood glucose were detected in doses of up to 160 U nasal insulin (4). A recent study on different doses of nasal insulin proposed that 160 U might be necessary to introduce acute profound effects on both the central and the peripheral nervous system (10). A variety of additives have been tested to enhance the absorption of intranasally applied insulin into the bloodstream to facilitate glucose lowering effects for the treatment of diabetes

(11,12). However, this is beyond the scope of the present review which focuses on the application of regular human insulin.

Using the intranasal administration of human insulin, as well as other methods to stimulate brain insulin action, a number of human brain areas were characterized to respond to the peptide. This led to functional consequences on memory, mood, eating behavior, and body weight, as well as metabolism in the entire organism (for recent review of functions of brain insulin in humans, please see (4,5)). These studies also illustrate that responses to insulin application in the brain are not uniform. A substantial number of persons were found to be brain insulin-resistant. This condition was, furthermore, linked to a number of potential behavioral and metabolic consequences (for recent reviews, please see (4,5)).

Besides addressing physiologic and pathophysiologic aspects of brain insulin action in humans, several studies used intranasal insulin with a therapeutic intention:

Nasal insulin has been administered to children with high risk for type 1 diabetes (13–16). This disease is caused by an autoimmune destruction of the insulin-producing pancreatic beta cells. Nasal insulin was applied to determine whether this treatment induces sufficient immune tolerance to prevent onset of disease. Up to now, however, there are no reports that the onset of the disease is positively influenced by nasal insulin.

In patients with the rare genetic Phelan-McDermid syndrome, nasal insulin administration was observed to have beneficial effects on cognition and social skills (17,18).

In addition to these trials, which enrolled mainly children, a number of studies were conducted in adults: Nasal insulin was also used in trials to improve cognitive function in patients with mild cognitive impairments or in early stages of Alzheimer's disease (19–25). Since positive effects on cognition and related biomarkers were reported, follow-up trials are under way (e.g., [clinicaltrials.gov NCT01767909](https://clinicaltrials.gov/ct2/show/study/NCT01767909)).

Nasal insulin administration acutely reduced cigarette craving in smokers (26). Intranasal insulin also improved olfaction in a small-scale trial on patients with an impaired sense of

smell (27). in trials on patients with schizophrenia (28–30), bipolar disorder (31), or major depression (32). However, it did not show any effect on disease control.

Despite the use of intranasal insulin in many clinical studies in humans, only a limited number of these trials systematically reported safety aspects. Furthermore, the safety of intranasal insulin application has not yet been reviewed in the literature. From the evidence available on possible side effects and adverse reactions to the intranasal application of human insulin, we therefore include a detailed overview of the safety aspects of this technique. We also provide data on the temporal stability of human insulin after repacking into spray flasks.

Methods

Data source

We carried out a broad search of the available English-language literature. The electronic search was performed using MEDLINE. Articles published between 1999 and 2017 were included, with the cutoff date November 2nd, 2017. Prior to 1999, no clinical data on the impact of intranasal insulin and its side effects was provided in the literature. The following search terms were used: intranasal insulin, nasally insulin, nasal insulin. Bibliographies of current reviews on brain insulin were also analyzed (2,4–6,33,34).

Literature Screening

Study selection was performed on two levels of study screening (see Fig. 1). First, abstracts were reviewed for the following exclusion criteria: publication of abstracts only, comments, and reviews, animal or in vitro studies, and languages other than English. Although intranasal insulin has been tested in a number of studies in animals (n=33), this is beyond the scope of the current review.

Full articles were then obtained for all manuscripts accepted on the first level. For level two screening, inclusion required that the studies contained at least one of the following pieces of information: insulin dose, insulin product, study population. If a manuscript provided lacked information on safety, we requested information on this issue from the authors.

Although the studies included could be of any design, human intranasal insulin as the study product was a prerequisite. All outcomes and adverse side effects were excerpted. In studies reporting adverse side effects, we endeavored to determine both the number of patients evaluated and the evaluation of chronic or acute application as well as the nature of any side effects in the placebo or the verum group. All articles were screened for effects on blood glucose and the appearance of hypoglycemia. In many studies, however, there was no mention of the the occurrence of adverse side effects. In addition, we included the main

outcome for all manuscripts. Multiple publications describing the same cohorts of patients were identified and entered into the catalog only once to avoid duplcounting.

Stability

We tested the stability of the insulin product Actrapid, since this was the human insulin product used in most of the studies. Insulin content of the spray solutions was assessed by high-performance liquid chromatography (HPLC) according to recommendations of the FDA and the European Pharmacopoeia (Ph. Eur.). USP Insulin Human RS (USP, Rockville, MD, United States) was used as a reference standard. Three batches (8 spray flasks each) of Actrapid insulin 100 U/ml (Novo Nordisk, Bagsvaerd, Denmark) were prepared by transferring 6 ml of Actrapid insulin solution into sterile 10-ml screw cap bottles under aseptic conditions. Each bottle was then closed with a sterile screw cap. Four flasks from each batch were stored at 2-8°C, while the others four were stored at room temperature (<25°C). At days 0, 14, 28 and 57, flasks were analyzed after diluting an aliquot in 0.01N hydrochloric acid.

Measurements in triplicate were performed on a modular HPLC system (Shimadzu, Kyoto, Japan) equipped with an octadecyl silica gel column (Luna-Omega-C 18, 250 mm x 4.6 mm, 5 µm particle size, Phenomenex, Aschaffenburg, Germany) interfaced to a photo diode array detector (SPD-M20A) measuring at 214 nm. The column oven temperature was maintained at 40°C, and the injection volume was 10 µL with a mobile phase flow of 1 ml/min. Chromatograms were analyzed by LCsolution (Shimadzu, Kyoto, Japan).

As recommended in the monography “insulin human” of the European Pharmacopoeia, the resolution of HPLC peaks of human insulin and porcine insulin was tested with a resulting resolution of 1.24. Capacity factors, separation efficiencies and tailing factors were within the limits recommended by the FDA.

Results

A flow diagram outlining the systematic review process is provided in Fig. 1. The initial literature research identified 409 articles for screening, 35 of which were excluded since the full text article was not available. Of the 374 articles reviewed, 309 did not meet inclusion criteria. Altogether, 65 articles were therefore suitable for analysis.

The results of 38 studies with acute administration of intranasal insulin are summarized in Table 1. A total of 1092 persons participated in these studies; nasal insulin doses ranged between 10 U and 160 U. No cases of hypoglycemia and no severe adverse events were reported. Adverse events and main outcomes are summarized in Table 1.

The results of 18 studies with chronic administration of intranasal insulin are summarized in Table 2. These studies included 832 persons with treatment duration of between 21 days and 9.7 years. Daily nasal insulin doses ranged between 20 U and 160 U or 0.5 – 1.5 U/kg body weight. One case of symptomatic hypoglycemia was reported during treatment with placebo spray (35). No cases of severe hypoglycemia were recorded.

While no severe side effects were reported in any of the included studies, most manuscripts contained information on other adverse effects. These are summarized in Table 2 and aggregated by category in Table 3.

Stability results

None of the analyzed manuscripts contained any information on the stability of nasal insulin preparations. We therefore tested the temporal stability of insulin after repacking into nasal spray flasks under two storage conditions: at room temperature (<25°C) and under refrigeration (2-8°C). No visible changes were observed. Mean recovery rates were 98.8% (day 28) and 97.1% (day 57) of the initial concentration under refrigeration and 100.4% (day 28) and 98.1% (day 57) of the initial concentration at room temperature respectively (Fig. 2).

Inspection of the HPLC profiles revealed no accumulation of insulin degradation products over time.

Discussion

Only half of the 38 identified publications on acute effects of intranasal human insulin contained information on possible side effects. The majority of the manuscripts reporting the chronic application of nasal insulin also provided information on possible side effects. Fortunately, upon personal contact, authors of most of the remaining publications provided us with this information. Besides systematically aggregating this safety information, we provide measurements on the stability of human insulin after repacking into spray flasks for up to 3 months.

The majority of the identified studies used human insulin manufactured by Novo Nordisc (product name Actrapid or Novolin R). Some used insulin manufactured by Eli Lilly (product name Humulin R) or Sanofi (product names Insuman Rapid and H-Insulin 100). All these products contain similar recombinant human insulin and comparable excipients. While the dosage of excipients differs slightly between the products, none are believed to be in a range that cause harm when applied to the nose (36).

Safety

Since more than 1904 persons in the analyzed literature experienced no severe adverse events, intranasal insulin application appears to be relatively safe. Only one trial was specifically designed to test the safety of nasal administration of human insulin (35). It included 20 adults, who received 60 U human insulin and placebo in a double-blind randomized crossover design for 3 weeks (per arm). Insulin effects on the nose were addressed by an otorhinolaryngologist who performed a rhinoscopy, assessed mucociliary clearance, nasal airway patency, and nasal airflow resistance. No objective signs of acute adverse effects or functional disturbances in the nose were established. However, modest

subjective irritation was commonly reported by the participants. No changes in insulin antibody concentrations were detected.

One major safety concern of insulin administration is the risk of hypoglycemia. Indeed, a number of publications reported absorption of small amounts of the nasally applied peptide hormone into the bloodstream (37–42). Our review of the literature revealed that intranasal application of human insulin caused a decrease in blood glucose of between 0.2 mmol/l (4 mg/dl) and 0.5 mmol/l (9 mg/dl) in some studies (26,38,41–48). This decline in blood glucose persisted much longer than the temporary rise in circulating insulin post insulin nasal spray. Hence, this is presumably not only due to the spillover of nasal insulin into circulation, but also to enhanced peripheral insulin sensitivity caused by insulin action in the human brain (37,39,40). No cases of symptomatic or severe hypoglycemia after nasal insulin were reported.

Even if not reported in most publications, our own experience and personal communication with other scientists revealed that many subjects experience a short-term (< 5min) burning sensation in the nose directly after spray application. In one case, this persisted for about 24 h (19). Since this burning sensation was also frequently reported after placebo spray, it is probably caused by the excipients and not by the actual human insulin. Furthermore, one case of nose bleed after acute administration of 40 U nasal insulin has been reported so far (19). There are no reports of participants who prematurely discontinued a study due to side effects.

In a study in longtime smokers who had to abstain from smoking before spray application (26), a number of additional side effects were reported (see Table 1). To date, these particular side effects following acute application of nasal insulin have never been reported elsewhere, suggesting that nicotine withdrawal played a role here.

No further side effects were reported in the 1092 persons studied after acute administration of nasal insulin.

As in acute application, chronic treatment resulted in local side effects in the nasal area. A number of infections occurred during chronic treatment with nasal insulin. However, frequencies were comparable between insulin and placebo, and since infections are common in the patient populations studied, it is unlikely that nasal insulin alters the immune system in a way that predisposes to infectious diseases. A number of other side effects were reported less frequently, none of which were considered severe by the respective investigators. Taken together, the intranasal application of insulin appears to be relatively safe in both an acute and a chronic setting. All reported side effects were not severe and no subjects were reported to have been excluded due to adverse events. However, local side effects of long-term exposure of the nasal mucosa to insulin have not yet been extensively studied and future studies are therefore necessary to address this issue.

Stability

Our measurements revealed the chemical stability of human insulin after repacking it into spray flasks for up to 57 days. In line with earlier investigations (49), HPLC analysis revealed that the container system did not significantly influence the stability of human insulin solution.

Perspective – challenges for clinical use

As nasal insulin is relatively safe and stable after repacking in spray flasks, it is an appropriate tool to assess brain insulin effects in humans. The insulin formulations currently available can be used in acute and chronic clinical trials. However, nasal application often induces local effects such as a burning sensation in the nose. Improved insulin preparations for nasal use would therefore be advantageous to future studies and possible therapeutic application in patients.

Acknowledgements

We thank Suzanne Craft (Wake Forest University School of Medicine, Winston-Salem, USA), Leonard C. Harrison (Eliza Hall Institute of Medical Research, Victoria, Australia), Jessica Freiherr (Department of Diagnostic and Interventional Neuroradiology, RWTH Aachen University, Aachen, Germany), Hartmut Schächinger (Institute of Psychobiology, Division of Clinical Psychophysiology, University of Trier, Trier, Germany), Abimbola A. Akintola (Leiden University Medical Centre, Leiden, The Netherlands) and Roger S. McIntyre (University of Toronto, Toronto, Canada) for providing information on the side effects of nasal insulin in their studies.

Funding

Part of this work was supported by a grant (01GI0925) from the Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.), and by the Helmholtz Alliance ICEMED-Imaging and Curing Environmental Metabolic Diseases.

Conflict of interest

None of the authors has any conflict of interest of direct relevance to the contents of this study.

Figure Legend

Figure 1

Flow diagram of the literature search

References

1. Vogt MC, Brüning JC. CNS insulin signaling in the control of energy homeostasis and glucose metabolism - from embryo to old age. *Trends Endocrinol Metab TEM*. 2013 Feb;24(2):76–84.
2. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. *Diabetes*. 2014 Jul;63(7):2232–43.
3. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of Brain Insulin Receptor in Control of Body Weight and Reproduction. *Science*. 2000 Sep 22;289(5487):2122–5.
4. Heni M, Kullmann S, Preissl H, Fritsche A, Häring H-U. Impaired insulin action in the human brain: causes and metabolic consequences. *Nat Rev Endocrinol*. 2015 Dec;11(12):701–11.
5. Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Häring H-U. Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. *Physiol Rev*. 2016 Oct;96(4):1169–209.
6. Spetter M, Hallschmid M. Intranasal neuropeptide administration to target the human brain in health and disease. *Mol Pharm*. 2015 Apr 16;
7. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. *Nat Neurosci*. 2002 Jun;5(6):514–6.
8. Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, et al. Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition. *J Alzheimers Dis JAD*. 2015;47(3):715–28.
9. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. *Diabetes*. 1999 Mar;48(3):557–63.
10. Kullmann S, Veit R, Peter A, Pohmann R, Scheffler K, Häring H-U, et al. Dose dependent effects of intranasal insulin on resting-state brain activity. *J Clin Endocrinol Metab*. 2017 Oct 31;
11. Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: Past, present and future. *Int J Pharm Investig*. 2016 Mar;6(1):1–9.
12. Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. *Adv Drug Deliv Rev*. 2007 Dec 22;59(15):1521–46.
13. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. *Diabetes Care*. 2004 Oct;27(10):2348–55.
14. Haavisto LE, Vahlberg TJ, Sipilä JI. A follow-up study with acoustic rhinometry in children using nasal insulin. *Rhinology*. 2010 Mar;48(1):95–9.
15. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies

- conferring increased risk of disease: a double-blind, randomised controlled trial. *Lancet Lond Engl*. 2008 Nov 15;372(9651):1746–55.
16. Ryhänen SJ, Härkönen T, Siljander H, Näntö-Salonen K, Simell T, Hyöty H, et al. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes. *Diabetes Care*. 2011 Jun;34(6):1383–8.
 17. Schmidt H, Kern W, Giese R, Hallschmid M, Enders A. Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. *J Med Genet*. 2009 Apr;46(4):217–22.
 18. Zwanenburg RJ, Bocca G, Ruiters SAJ, Dillingh JH, Flapper BCT, van den Heuvel ER, et al. Is there an effect of intranasal insulin on development and behaviour in Phelan-McDermid syndrome? A randomized, double-blind, placebo-controlled trial. *Eur J Hum Genet EJHG*. 2016 Dec;24(12):1696–701.
 19. Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. *Neurobiol Aging*. 2006 Mar;27(3):451–8.
 20. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. *Neurology*. 2008 Feb 5;70(6):440–8.
 21. Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. *J Alzheimers Dis JAD*. 2011;26(3):477–84.
 22. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *J Alzheimers Dis JAD*. 2008 Apr;13(3):323–31.
 23. Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. *J Alzheimers Dis JAD*. 2013;35(4):789–97.
 24. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Arch Neurol*. 2012 Jan;69(1):29–38.
 25. Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. *J Alzheimers Dis*. 2017 Jan 1;Preprint(Preprint):1–10.
 26. Hamidovic A, Khafaja M, Brandon V, Anderson J, Ray G, Allan AM, et al. Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial. *Mol Psychiatry*. 2017 Feb 28;
 27. Schöpf V, Kollndorfer K, Pollak M, Mueller CA, Freiherr J. Intranasal insulin influences the olfactory performance of patients with smell loss, dependent on the body mass index: A pilot study. *Rhinology*. 2015 Dec;53(4):371–8.
 28. Fan X, Copeland PM, Liu EY, Chiang E, Freudenreich O, Goff DC, et al. No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia. *J Clin Psychopharmacol*. 2011 Apr;31(2):231–4.

29. Fan X, Liu E, Freudenreich O, Copeland P, Hayden D, Ghebremichael M, et al. No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. *J Clin Psychopharmacol*. 2013 Apr;33(2):226–30.
30. Li J, Li X, Liu E, Copeland P, Freudenreich O, Goff DC, et al. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. *Schizophr Res*. 2013 May;146(1–3):40–5.
31. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. *Bipolar Disord*. 2012 Nov;14(7):697–706.
32. Cha DS, Best MW, Bowie CR, Gallagher LA, Woldeyohannes HO, Soczynska JK, et al. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. *J Affect Disord*. 2017 Mar 1;210:57–65.
33. Lee S-H, Zabolotny JM, Huang H, Lee H, Kim Y-B. Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. *Mol Metab*. 2016 Aug;5(8):589–601.
34. Freiherr J, Hallschmid M, Frey WH, Brünner YF, Chapman CD, Hölscher C, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. *CNS Drugs*. 2013 Jul;27(7):505–14.
35. Kupila A, Sipilä J, Keskinen P, Simell T, Knip M, Pulkki K, et al. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults. *Diabetes Metab Res Rev*. 2003 Oct;19(5):415–20.
36. Hamidovic A. Position on zinc delivery to olfactory nerves in intranasal insulin phase I-III clinical trials. *Contemp Clin Trials*. 2015 Nov;45(Pt B):277–80.
37. Heni M, Kullmann S, Ketterer C, Guthoff M, Linder K, Wagner R, et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. *Diabetologia*. 2012;55(6):1773–82.
38. Gancheva S, Koliaki C, Bierwagen A, Nowotny P, Heni M, Fritsche A, et al. Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. *Diabetes*. 2015 Jun;64(6):1966–75.
39. Heni M, Wagner R, Kullmann S, Gancheva S, Roden M, Peter A, et al. Hypothalamic and Striatal Insulin Action Suppresses Endogenous Glucose Production and May Stimulate Glucose Uptake During Hyperinsulinemia in Lean but not in Overweight Men. *Diabetes*. 2017 Feb 7;
40. Heni M, Wagner R, Kullmann S, Veit R, Mat Husin H, Linder K, et al. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. *Diabetes*. 2014 Dec;63(12):4083–8.
41. Feld GB, Wilhem I, Benedict C, Rüdell B, Klameth C, Born J, et al. Central Nervous Insulin Signaling in Sleep-Associated Memory Formation and Neuroendocrine Regulation. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2016 May;41(6):1540–50.

42. Thienel M, Wilhelm I, Benedict C, Born J, Hallschmid M. Intranasal insulin decreases circulating cortisol concentrations during early sleep in elderly humans. *Neurobiol Aging*. 2017 Jun;54:170–4.
43. Heni M, Kullmann S, Ketterer C, Guthoff M, Linder K, Wagner R, et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. *Diabetologia*. 2012 Jun;55(6):1773–82.
44. Benedict C, Kern W, Schultes B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. *J Clin Endocrinol Metab*. 2008 Apr;93(4):1339–44.
45. Hallschmid M, Higgs S, Thienel M, Ott V, Lehnert H. Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. *Diabetes*. 2012 Apr;61(4):782–9.
46. Santiago JCP, Hallschmid M. Central Nervous Insulin Administration before Nocturnal Sleep Decreases Breakfast Intake in Healthy Young and Elderly Subjects. *Front Neurosci*. 2017;11:54.
47. Br nner YF, Benedict C, Freiherr J. Intranasal insulin reduces olfactory sensitivity in normosmic humans. *J Clin Endocrinol Metab*. 2013 Oct;98(10):E1626-1630.
48. Stockhorst U, de Fries D, Steingrueber H-J, Scherbaum WA. Unconditioned and conditioned effects of intranasally administered insulin vs placebo in healthy men: a randomised controlled trial. *Diabetologia*. 2011 Jun;54(6):1502–6.
49. Sadeghipour F, Bonnabry P. The stability of soluble insulin in plastic syringes. 2011;
50. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. *Diabetes*. 1999 Mar 1;48(3):557–63.
51. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. *Nat Neurosci*. 2002 Jun;5(6):514–6.
52. Bohringer A, Schwabe L, Richter S, Schachinger H. Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. *Psychoneuroendocrinology*. 2008 Nov;33(10):1394–400.
53. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *J Alzheimers Dis JAD*. 2008 Apr;13(3):323–31.
54. Guthoff M, Grichisch Y, Canova C, Tschritter O, Veit R, Hallschmid M, et al. Insulin modulates food-related activity in the central nervous system. *J Clin Endocrinol Metab*. 2010 Feb;95(2):748–55.
55. Krug R, Benedict C, Born J, Hallschmid M. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. *J Clin Endocrinol Metab*. 2010 Dec;95(12):E468-472.
56. Stingl KT, Kullmann S, Guthoff M, Heni M, Fritsche A, Preissl H. Insulin modulation of magnetoencephalographic resting state dynamics in lean and obese subjects. *Front Syst Neurosci*. 2010;4:157.

57. Benedict C, Brede S, Schiöth HB, Lehnert H, Schultes B, Born J, et al. Intranasal Insulin Enhances Postprandial Thermogenesis and Lowers Postprandial Serum Insulin Levels in Healthy Men. *Diabetes*. 2011 Jan 1;60(1):114–8.
58. Guthoff M, Stingl KT, Tschritter O, Rogic M, Heni M, Stingl K, et al. The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. *PLoS One*. 2011 May 11;6(5):e19482.
59. Grichisch Y, Çavuşoğlu M, Preissl H, Uludağ K, Hallschmid M, Birbaumer N, et al. Differential effects of intranasal insulin and caffeine on cerebral blood flow. *Hum Brain Mapp*. 2012 Feb;33(2):280–7.
60. Ketterer C, Heni M, Stingl K, Tschritter O, Linder K, Wagner R, et al. Polymorphism rs3123554 in CNR2 reveals gender-specific effects on body weight and affects loss of body weight and cerebral insulin action. *Obes Silver Spring Md*. 2014 Mar;22(3):925–31.
61. Jauch-Chara K, Friedrich A, Rezmer M, Melchert UH, G Scholand-Engler H, Hallschmid M, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. *Diabetes*. 2012 Sep;61(9):2261–8.
62. Kullmann S, Frank S, Heni M, Ketterer C, Veit R, Häring H-U, et al. Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. *Neuroendocrinology*. 2013;97(2):176–82.
63. Iwen KA, Scherer T, Heni M, Sayk F, Wellnitz T, Machleidt F, et al. Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans. *J Clin Endocrinol Metab*. 2014 Feb;99(2):E246-251.
64. Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. *Diabetes Care*. 2014;37(3):751–9.
65. Zhang H, Hao Y, Manor B, Novak P, Milberg W, Zhang J, et al. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. *Diabetes*. 2015 Mar;64(3):1025–34.
66. Ferreira de Sá DS, Schulz A, Streit FE, Turner JD, Oitzl MS, Blumenthal TD, et al. Cortisol, but not intranasal insulin, affects the central processing of visual food cues. *Psychoneuroendocrinology*. 2014 Dec;50:311–20.
67. Schilling TM, Ferreira de Sá DS, Westerhausen R, Strelzyk F, Larra MF, Hallschmid M, et al. Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation. *Hum Brain Mapp*. 2014 May;35(5):1944–56.
68. Brünner YF, Kofoet A, Benedict C, Freiherr J. Central insulin administration improves odor-cued reactivation of spatial memory in young men. *J Clin Endocrinol Metab*. 2015 Jan;100(1):212–9.
69. Kullmann S, Heni M, Veit R, Scheffler K, Machann J, Häring H-U, et al. Intranasal insulin enhances brain functional connectivity mediating the relationship between adiposity and subjective feeling of hunger. *Sci Rep*. 2017 May 9;7(1):1627.
70. Kullmann S, Fritsche A, Wagner R, Schwab S, Häring H-U, Preissl H, et al. Hypothalamic insulin responsiveness is associated with pancreatic insulin secretion in humans. *Physiol Behav*. 2017 Jul 1;176:134–8.

71. Kullmann S, Heni M, Veit R, Scheffler K, Machann J, Häring H-U, et al. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. *Diabetes Care*. 2015 Jun;38(6):1044–50.
72. Brünner YF, Rodriguez-Raecke R, Mutic S, Benedict C, Freiherr J. Neural correlates of olfactory and visual memory performance in 3D-simulated mazes after intranasal insulin application. *Neurobiol Learn Mem*. 2016 Oct;134 Pt B:256–63.
73. Rodriguez-Raecke R, Yang H, Bruenner YF, Freiherr J. Intranasal Insulin Boosts Gustatory Sensitivity. *J Neuroendocrinol*. 2017 Jan;29(1).
74. Akintola AA, van Opstal AM, Westendorp RG, Postmus I, van der Grond J, van Heemst D. Effect of intranasally administered insulin on cerebral blood flow and perfusion; a randomized experiment in young and older adults. *Aging*. 2017 Mar 14;9(3):790–802.
75. Opstal AM van, Akintola AA, Elst M van der, Westendorp RG, Pijl H, Heemst D van, et al. Effects of intranasal insulin application on the hypothalamic BOLD response to glucose ingestion. *Sci Rep*. 2017 Oct 17;7(1):13327.
76. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. *Psychoneuroendocrinology*. 2004 Nov;29(10):1326–34.
77. Hallschmid M, Benedict C, Schultes B, Fehm H-L, Born J, Kern W. Intranasal insulin reduces body fat in men but not in women. *Diabetes*. 2004 Nov;53(11):3024–9.
78. Benedict C, Dodt C, Hallschmid M, Lepiorz M, Fehm HL, Born J, et al. Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. *Metabolism*. 2005 Oct;54(10):1356–61.
79. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2007 Jan;32(1):239–43.
80. Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. *Int J Obes* 2005. 2008 Feb;32(2):275–82.
81. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. *Lancet Lond Engl*. 2008 Nov 15;372(9651):1746–55.
82. Furlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. *Diabetes*. 2011 Apr;60(4):1237–45.
83. Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. *J Alzheimers Dis JAD*. 2017 Mar 29;
84. Scherer T, Wolf P, Smajis S, Gaggini M, Hackl M, Gastaldelli A, et al. Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects. *J Clin Endocrinol Metab*. 2017 Apr 1;102(4):1325–32.

Table 1 – Major outcomes and safety details of studies with acute application intranasal human insulin

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Kern et al., 1999 (50)	120 U over 90 minutes versus Placebo (cross-over)	18 volunteers	H-Insulin 100 Sanofi; Sanofi	Changes in auditory evoked potentials, no effect on plasma insulin, glucose or plasma norepinephrine levels	No information	none
Born et al., 2002 (51)	40 U once versus placebo (randomized parallel)	8 healthy subjects (insulin arm), 5 healthy subjects (placebo arm)	No information	Increase in CSF insulin, no effect on serum insulin	No information	No information
Reger et al., 2006 (19)	20 or 40 U or placebo once (cross-over)	26 memory-impaired subject and 35 normal controls	Novolin R, Novo Nordisk	Improved verbal memory, no effect on plasma insulin or blood glucose	Nose bleed (1 subject at 40 U), nose soreness for about 24h (treatment not specified)	none
Benedict et al., 2008 (44)	160 U versus placebo once (cross-over)	32 normal-weight subjects (18 females)	Actrapid, Novo Nordisk	Decreased food intake in men, but not in women, improved memory in women, but not in men	Decrease in blood glucose (by about 0.24 mmol/l)	none
Bohringer et al., 2008 (52)	40 U versus placebo once (randomized parallel)	26 healthy young males	Actrapid, Novo Nordisk	Diminished cortisol response to the Trier social stress test	none	none
Mark A. Reger et al., 2008 (53)	10, 20, 40, 60 U versus placebo once (cross-over)	59 controls and 33 memory-impaired patients	Novolin R, Novo Nordisk	Improved verbal memory, peak effect with 20 U no effect on plasma insulin or blood glucose	Personal communication: Some cases of rhinitis, no other side effects.	none
Guthoff et al., 2010 (54)	160 U versus placebo once (cross-over)	9 healthy subjects (5 males)	Actrapid, Novo Nordisk	Altered processing of food pictures (assessed by fMRI)	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Krug et al., 2010 (55)	160 U versus placebo once (cross-over)	14 healthy postmenopausal women	Actrapid, Novo Nordisk	No effect on food intake, enhanced memory	Personal communication: tingling or mild burning sensation in the nose in some participants; no other AEs	none
Stingl et al., 2010 (56)	160 U once versus placebo (cross-over)	10 lean/10 overweight healthy volunteers	Actrapid, Novo Nordisk	Changes in resting state dynamics (assessed by MEG)	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Benedict et al., 2011 (57)	160 U versus Placebo once (cross-over)	19 healthy men	Actrapid, Novo Nordisk	Enhanced postprandial thermogenesis, lower postprandial circulating insulin and C-peptide levels	Personal communication: tingling or mild burning sensation in the nose in some participants; no other AEs	none
Fan et al., 2011 (28)	40 U versus placebo once (randomized parallel)	30 patients with schizophrenia	Humulin, Eli Lilly	No effect on verbal memory or sustained attention	No effect on plasma glucose	none
Guthoff et al., 2011 (58)	160 U versus placebo once (cross-over)	10 lean and 10 obese subject	Actrapid, Novo Nordisk	Altered cerebral processing of food pictures in lean, but not obese (assessed by MEG)	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Stockhorst et al., 2011 (48)	20 U once (randomized parallel)	32 healthy young subjects	Insuman Rapid, Sanofi	Conditioned increase in peripheral insulin	Slight decline in blood glucose, no adverse side effects	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Stein et al., 2011 (21)	60 U (n=16) versus placebo (n=16) 4 times daily for 2 days (total 480 U insulin) (parallel-design)	32 patients with mild to moderate Alzheimer's disease (16 females treated with nasal insulin)	Humulin, Eli Lilly	No effect of nasal insulin on memory	Personal communication: no side effects	Personal communication: No hypoglycemia was measured
Grichisch et al., 2012 (59)	160 U versus oral caffeine (200mg) once (cross-over)	8 healthy subjects (3 males)	Actrapid, Novo Nordisk	No effect on global cerebral blood flow, i.e. no direct vasodilatory effect of nasal insulin	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	Personal communication: none
Hallschmid et al., 2012 (45)	160 U versus placebo once (randomized parallel)	30 healthy women	Actrapid, Novo Nordisk	Decreased postprandial appetite, decreased postprandial intake of chocolate cookies	Slight decrease in plasma glucose	none
M Heni et al., 2012; Ketterer et al., 2014 (43,60)	160 U versus Placebo once (cross-over)	103 volunteers	Actrapid, Novo Nordisk	Change in HOMA-IR and change in regular brain activity, no effect on cortisol levels	Decline in blood glucose by about 0.2 mmol/l, burning sensation in the nose in some participants (no more than 5 minutes)	none
Jauch-Chara et al., 2012 (61)	40 U versus placebo once (cross-over)	15 healthy men	Actrapid, Novo Nordisk	Increased brain ATP and phosphocreatine levels	No effect on blood glucose (measured every 5 minutes), no other side effects reported	none
Brünner et al., 2013 (47)	40 U once versus placebo (cross-over)	14 healthy subjects (7 females)	Actrapid, Novo Nordisk	Decrease in olfactory threshold	Slight decline in blood glucose (about 0.2 mmol/l)	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Kullmann et al., 2013 (62)	160 U once versus placebo (cross-over)	17 female volunteers	Actrapid, Novo Nordisk	Modification of reward processes and prefrontal brain activity, assessed by fMRI	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Heni et al., 2014 (40)	160 U once versus placebo during systemic hyperinsulinemia (cross-over)	10 lean and 5 obese healthy men	Actrapid, Novo Nordisk	Improved peripheral insulin sensitivity, modulation of hypothalamic activity (assessed by fMRI), change in heart rate variability	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Iwen et al., 2014) (63)	160 U once versus placebo (cross-over)	14 healthy men	Actrapid, Novo Nordisk	Decrease in circulating free fatty acids and lipolysis	Personal communication: tingling or mildly burning sensation in the nose in some participants; no other AEs	none
Novak et al., 2014; Zhang et al., 2015 (64,65)	40 U once versus saline (randomized parallel)	15 patients with type 2 diabetes, 14 controls	Novolin R, Novo Nordisk	Improvement in cognitive function, change in cerebral blood flow (assessed by MRI)	No serious adverse events, no nasal irritation, no allergic reactions	none
Ferreira de Sá et al., 2014; Schilling et al., 2014 (66,67)	40 U insulin (n=13), 30mg Cortisol (n=12), 30mg Cortisol + 40 U insulin (n=15), placebo (n=14) (parallel-design)	54 healthy volunteers	Actrapid, Novo Nordisk	No effect of insulin on processing of food cues	Personal communication: tingling or mildly burning sensation in the nose in some participants; no other AEs	Personal communication: none
Brünner et al., 2015 (68)	40U once versus placebo (cross-over)	18 male subjects	Actrapid, Novo Nordisk	Improved, delayed but not immediate odor-cued recall of spatial memory	None	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Gancheva et al., 2015 (38)	160 U once versus placebo (cross-over)	10 patients with type 2 diabetes (1 female), 10 healthy volunteers (3 females)	Actrapid, Novo Nordisk	Improvement in hepatic energy metabolism and decline in liver fat content in lean subjects	Slight decline in blood glucose	none
Kullmann et al., 2015, 2017b, 2017a (69–71)	160 U once versus placebo (cross-over)	25 lean (10 female) and 23 (11 female) overweight healthy volunteers	Actrapid, Novo Nordisk	Change in regional brain activity (assessed by fMRI)	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Schöpf et al., 2015 (27)	40 U insulin (n=10), NaCl at later time point (n=7) once	10 patients with smell loss	Actrapid, Novo Nordisk	Improved olfactory sensitivity and intensity	Personal communication: No adverse events	Personal communication: none
Feld et al., 2016 (41)	160 U versus placebo (cross-over)	16 healthy men and 16 healthy women	Actrapid, Novo Nordisk	Increased growth hormone concentrations in the night-half following nasal insulin, impaired memory encoding on subsequent day	Temporary, slight decline in blood glucose	none
Brünner et al., 2016 (72)	40 U versus placebo once (cross-over)	16 healthy men	Actrapid, Novo Nordisk	No effect of nasal insulin on declarative memory or hippocampal activity	none	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Hamidovic et al., 2017 (26)	60 U versus placebo once	19 healthy smokers (cross-over) and 37 healthy smokers (parallel) abstained from smoking for 36h	Novolin R, Novo Nordisk	Reduction in nicotine craving, Increase in circulating cortisol during psychosocial stress	<ul style="list-style-type: none"> - Slight decrease in blood glucose - Rinorrhea (Placebo: N=1; Insulin: N=1) - Nasal irritation (Placebo: N=5, Insulin N=7) - Dizziness (Placebo: N=0, Insulin N=1) - Sweating (Placebo: N=0, Insulin N=2) - Headache (Placebo: N=0, Insulin N=1) - Confusion (Placebo: N=1, Insulin N=2) - Tingling in mouth (Placebo: N=0, Insulin N=1) - Shaking (Placebo: N=0, Insulin N=1) - Anxiety (Placebo: N=1, Insulin N=1) - Restlessness (Placebo: N=0, Insulin N=1) - Discomfort (Placebo: N=0, Insulin N=1) - Watering eyes (Placebo: N=0, Insulin N=2) 	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Heni et al., 2017 (39)	160 U versus placebo once during systemic hyperinsulinemia (cross-over)	11 lean and 10 overweight healthy men	Actrapid, Novo Nordisk	Improvement in peripheral insulin sensitivity by suppression of endogenous glucose production and stimulation of glucose uptake into tissue. Change in regional brain activity in hypothalamus and striatum, detailed characterization and mimicking of spillover of nasal insulin into circulation	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
Rodriguez-Raecke et al., 2017 (73)	40 U versus placebo once (cross-over)	24 healthy males	Actrapid, Novo Nordisk	Improved gustatory sensitivity	none	none
Santiago and Hallschmid, 2017 (46)	160 U versus placebo once (cross-over)	51 healthy (32 young and 19 elderly) men and women	Actrapid, Novo Nordisk	Reduced food intake, no effect on sleep patterns	Slight decline in blood glucose (around 0.48 mmol/l), no other side effects reported	none
Akintola et al., 2017 (74)	40 U versus placebo (cross-over)	19 adults (11 older and 8 young)	Actrapid, Novo Nordisk	Improved brain perfusion in occipital lobe and thalamus in older persons	No effect on blood glucose. No other side effects reported	none
Thienel et al., 2017 (42)	160 U versus placebo once (cross-over)	14 elderly and 30 young healthy subjects	Actrapid, Novo Nordisk	Reduced cortisol levels in the night half following nasal insulin in elderly, but not in young participants	Temporary slight decline in blood glucose	none

Studies on acute effects of nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Opstal et al., 2017 (75)	40 U versus placebo (cross-over)	8 healthy, normal weight adult male	Actrapid, Novo Nordisk	Enhanced effect of oral glucose ingestion on the hypothalamus	Personal communication: One participant with runny nose after insulin and placebo spray, no other side effects	none
Kullmann et al., 2017 (10)	40 U, 80 U, 160 U versus placebo (four-way cross-over)	9 healthy men	Actrapid, Novo Nordisk	Dose-dependent effect on regional brain activity and on the autonomic nervous system	Personal communication: burning sensation in the nose in some participants (no more than 5 minutes); no other AEs	none
		1092 persons acutely treated with nasal insulin				

Table 2 – Major outcomes and safety details of studies with chronic application intranasal human insulin

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Kupila et al., 2003 (35)	60 U once daily over 3 weeks versus Placebo (cross-over)	20 non-diabetic adults (11 females)	Actrapid, Novo Nordisk	No effect on blood glucose	No nasal adverse effects (rhinoscopy and further tests before and after treatment), 11 subjects with nasal stinging or unpleasant odor, no induction of diabetes-related auto-antibodies	one symptomatic hypoglycemia (during placebo treatment)
Benedict et al., 2004 (76)	4x40 U/d for 8 weeks or placebo (randomized parallel)	38 healthy volunteers (24 males) (age 18 to 34 years)	Actrapid, Novo Nordisk	Improved declarative memory, reduced anger, enhanced self-confidence, lower serum cortisol in insulin group	Personal communication: tingling or mildly burning sensation after application in the nose in some participants; some subjects' partners complained about odor; no other AEs.	none
Hallschmid et al., 2004 (77)	4x40 U/d for 8 weeks or placebo (randomized parallel)	40 healthy subjects (24 males)	Actrapid, Novo Nordisk	Reduction of body weight in men, body weight gain in women	No effect on glucose and insulin levels. Personal communication: tingling or mildly burning sensation after application in the nose in some participants; some subjects' partners complained about odor; no other AEs.	none
Harrison et al., 2004 (13)	40 U daily versus placebo for the first 10 days, thereafter 2 consecutive days weekly for 6 month (randomized parallel)	38 children with one or more auto-antibodies	Humulin, Eli Lilly	Induction on immune changes consistence with mucosal tolerance to insulin	No local or systemic adverse events	none

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Benedict et al., 2005 (78)	Acute study: 20 U every 10 min over 2h (240 U) versus placebo (cross-over) Chronic study: 4x40 U/d for 8 weeks or placebo (randomized parallel)	8 young men (acute study), 8 men and 8 women (chronic study)	Actrapid, Novo Nordisk	Acute, but not chronic rise in blood pressure, no effect on heart rate	No information	none
Benedict et al., 2007 (79)	4x40 U/d human insulin or placebo or 4x40 U/d insulin aspart for 8 weeks (randomized parallel)	36 young, healthy, lean men	Actrapid, Novo Nordisk	Enhanced insulin induced memory improvement after intranasal insulin aspart	No effect on glucose. Personal communication: tingling or mildly burning sensation after application in the nose in some participants; some subjects' partners complained about odor; no other AEs.	none
Hallschmid et al., 2008 (80)	4x40 U/d for 8 weeks or placebo (randomized parallel)	30 obese men	Actrapid, Novo Nordisk	Improvement of declarative memory and mood, no effect on body weight, reduction of ACTH and cortisol	Personal communication: tingling or mildly burning sensation after application in the nose in some participants; some subjects' partners complained about odor; no other AEs.	none

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Haavisto et al., 2010; Näntö-Salonen et al., 2008; Ryhänen et al., 2011 (14,16,81)	1 U/kg versus placebo once daily, median duration 1.8 years (range 0-9.7 years) (randomized parallel)	224 infants positive for 2 or more auto-antibodies and 40 siblings	Actrapid, Novo Nordisk	No effect on the progression of type 1 diabetes, no increase in auto-antibodies during treatment	Nasal irritation (75% insulin group and 72% placebo group), symptomatic time per treatment month longer in the placebo group, no difference in nasal mucosa in a subgroup, nasal discharge 83% insulin group and 86% placebo group), cough 75% insulin group and 77% placebo group) and fever (75% insulin group and 87% placebo group), middle ear (and sinus infections 32% insulin group and 42% placebo group), gastrointestinal symptoms 60% insulin group and 64% placebo group), no difference in more rare adverse events	No hypoglycemia

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
M. A. Reger et al., 2008 (20)	20 U twice daily versus placebo for 21 days (randomized parallel)	25 cognitive-impaired subjects	Novolin R, Novo Nordisk	Improved verbal memory, improved attention, increased A β 40/42 ratio, no effect on insulin and blood glucose	<ul style="list-style-type: none"> - No serious adverse events, - Headache (1 subject on insulin), - nasal dripping (2 subject on placebo, 1 subject on insulin), - weakness (1 subject on insulin), - sneezing (1 subject on placebo) 	Blood glucose between 60 and 70 mg/dL (1 insulin)
Schmidt et al., 2009 (17)	0.5-1.5 U/kg/d for one year, no placebo group	6 children with Phelan-McDermid syndrome (age 16 months to 9.5 years)	Actrapid, Novo Nordisk	Improvement in motor development, cognitive function and spontaneous activity	<ul style="list-style-type: none"> - changes in balance, extreme sensitivity to touch and general loss of interest (one patient), - intermittent nose bleeding (one patient) - no effect on HbA1c, cortisol or insulin auto-antibodies 	none
Fourlanos et al., 2011 (82)	40 U daily versus placebo for the first 10 days, thereafter 2 consecutive days weekly for 12 months (randomized parallel)	52 adults with recent onset type 2 diabetes	Humulin, Eli Lilly	Blunted insulin anti-body response, no effect on metabolism	Personal communication: no side effects	Personal communication: No hypoglycemia was measured

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
McIntyre et al., 2012 (31)	40 U daily versus placebo for 8 weeks (randomized parallel)	62 adults with bipolar I/II disorder	Novolin R, Novo Nordisk	Improvement of executive function	Insulin group: intranasal irritation (13.6%), anxiety (4.9%), nose bleed (2.9%). Placebo group: nasal irritation (21%), increased appetite (3.6%), light-headedness (2.4%)	none
Claxton et al., 2013; Craft et al., 2012 (23,24)	20 or 40 U or placebo daily for 4 months (randomized parallel)	104 cognitive-impaired patients	Novolin R, Novo Nordisk	Delayed progression of cognitive decline and PET assessed brain dysfunction	<ul style="list-style-type: none"> - No severe adverse events - lightheadedness and/or dizziness (Placebo: 10%, 20 U: 8%, 40 U: 13%) - headache (Placebo: 3%, 20 U: 8%, 40 U: 5%) - nose bleed (Placebo: 0%, 20 U: 8%, 40 U: 3%) - rhinitis (Placebo: 3%, 20 U: 17%, 40 U: 8%) - upper respiratory tract infections (Placebo: 7%, 20 U: 6%, 40 U: 3%) - Fall (Placebo: 7%, 20 U: 3%, 40 U: 3%) - Rush (Placebo: 7%, 20 U: 3%, 40 U: 3%) All these side effects in \leq 5 participants per group	none

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Fan et al., 2013; Li et al., 2013 (29) (30)	4x40 U/d (N=21) versus placebo (N=24) for 8 weeks (parallel-design)	45 patients with schizophrenia	Humulin, Eli Lilly	No improvement in schizophrenia symptoms or cognition. No effect on body weight, glucose or lipids.	No serious adverse events - Wheezing (insulin 10%; placebo 0%) - Coughing (insulin 10%; placebo 0%) - Trouble breathing (insulin 5%; placebo 0%) - Nasal congestion (insulin 10%; placebo 4%) - Hypersalivation (insulin 5%; placebo 0%) - Nausea (insulin 5%; placebo 0%) - Vomiting (insulin 5%; placebo 0%) - Numbness (insulin 5%; placebo 0%) - Poor concentration (insulin 10%; placebo 4%) - Confusion (insulin 5%; placebo 0%) - Insomnia (insulin 19%; placebo 0%) - Drowsiness (insulin 10%; placebo 0%) No patient withdrew from study on account of AEs	none

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
Zwanenburg et al., 2016 (18)	age 1-3 years 20 U/d, age 3-9 years 30 U/d, age 9-18 years 40 U/d for 18 months or placebo (stepped wedge design)	25 patients with Phelan-McDermid syndrome (1-16 years)	Humulin, Eli Lilly	No statistically significant improvement in cognitive function, significant effect on cognition and social skills and patients > 3 years	<ul style="list-style-type: none"> - No severe adverse events, - Transitory nasal irritation, - Mild pancreatitis (1 child under placebo after more than 5 months' treatment), - Nosebleeds and irritation of nasal area for 1 or 2 days (12 patients) 	Not measured
Cha et al., 2017 (32)	4x40 U/d versus placebo for 4 weeks (cross-over)	35 patients with major depressive disorder	Humulin, Eli Lilly	No effect on mood	Personal communication: Local irritation in the nose, no other side effects.	Personal communication: none
Craft et al., 2017 (83)	2x20 U/d (n=12) versus insulin detemir (n=12) versus placebo (n=12) for 4 months (parallel-design)	36 patients with mild cognitive impairment or Alzheimer's disease	Humulin, Eli Lilly	Better memory	No serious adverse events. Rhinitis and upper respiratory symptoms (most common). No further information available.	No information
Scherer et al., 2017 (84)	4x40 U/d (n=10) versus placebo (n=10) for 4 weeks (parallel-design)	20 healthy males	Actrapid, Novo Nordisk	No effect on body weight or intrahepatic lipids. Reduction of circulating branched-chain amino acids.	Mild burning sensation in the nose	none

Studies on effects of chronic nasal application of human insulin						
Author	Dose	Study population	Insulin product	Main outcome	Adverse side effects	Hypoglycemia
		832 persons treated with nasal insulin in studies with multiple administrations				

Table 3 – Overview about reported side effects of chronic application of nasal insulin in humans

	Näntö-Salonen et al., 2008 (81)	Fan et al., 2013 (29)	M. A. Reger et al., 2008 (20)	Craft et al., 2012 (24)	McIntyre et al., 2012 (31)	Zwanenburg et al., 2016 (18)	Schmidt et al., 2009 (17)	Craft et al., 2017 (83)
	264 children N=91 in each group were analyzed for AEs	45 patients with schizophrenia	25 cognitive-impaired patients	104 cognitive-impaired patients (N=30 with placebo, N=30 with 20 U and N=38 with 40 U)	62 adults with bipolar I/II disorder	25 children with Phelan-McDermid syndrome	6 children with Phelan-McDermid syndrome	
Nasal irritation / sneezing	75% (N=68) insulin group and 72% (N=66) placebo group	N=2 insulin group and N=0 placebo group	N=1 insulin group and N=0 placebo group	-	13.6% insulin group and 21% placebo group	N=12	-	
Nasal discharge / rhinitis	83% (N=76) insulin group and 86% (N=78) placebo group	-	N=2 insulin group and N=1 placebo group	Placebo: 3% (N=1), 20U: 17% (N=8), 40 U: 8% (N=4)	-	-	-	N=5 insulin group and N=2 placebo group
Nasal congestions	-	N=2 insulin group and N=1 placebo group	-	-	-	-	-	
Nose bleed	-	-	-	Placebo: 0%, 20U: 8% (N=6), 40 U: 3% (N=3)	2.9% insulin group	N=12	N=1	
Cough	75% (N=68) insulin group and 77% (N=70) placebo group	N=2 insulin group and N=0 placebo group	-	-	-	-	-	
Wheezing	-	N=2 insulin group and N=0 placebo group	-	-	-	-	-	

	Näntö-Salonen et al., 2008 (81)	Fan et al., 2013 (29)	M. A. Reger et al., 2008 (20)	Craft et al., 2012 (24)	McIntyre et al., 2012 (31)	Zwanenburg et al., 2016 (18)	Schmidt et al., 2009 (17)	Craft et al., 2017 (83)
Hypersalivation	-	N=1 insulin group and N=0 placebo group	-	-	-	-	-	
Fever	75% (N=68) insulin group and 87% (N=80) placebo group	-	-	-	-	-	-	
Middle ear and sinus infections	32% (N=30) insulin group and 42% (N=39) placebo group	-	-	-	-	-	-	
Upper respiratory tract infections	-	-	-	Placebo: 7%, 20U: 6%, 40 U: 3%	-	Frequency not specified	-	
Gastrointestinal symptoms	60% (N=56) insulin group and 64% (N=59) placebo group	N=2 insulin group and N=0 placebo group	-	-	-	Frequency not specified	-	N=1 insulin group and N=1 placebo group
Numbness	-	N=1 insulin group and N=0 placebo group	-	-	-	-	-	
Poor concentration/ confusion	-	N=3 insulin group and N=1 placebo group	-	-	-	-	-	
Insomnia	-	N=4 insulin group and N=0 placebo group	-	-	-	-	-	
Anxiety	-	-	-	-	4.9% insulin group	-	-	-

	Näntö-Salonen et al., 2008 (81)	Fan et al., 2013 (29)	M. A. Reger et al., 2008 (20)	Craft et al., 2012 (24)	McIntyre et al., 2012 (31)	Zwanenburg et al., 2016 (18)	Schmidt et al., 2009 (17)	Craft et al., 2017 (83)
Drowsiness / weakness	-	N=2 insulin group and N=0 placebo group	N=1 insulin group and N=0 placebo group	Placebo: 10%, 20 U: 8%, 40 U: 13%	2.4% placebo group	-	-	N=1 insulin group and N=0 placebo group
Fall	-	-	-	Placebo: 7%, 20 U: 3%, 40 U: 3%	-	-	-	
Headache	-	-	N=1 insulin group and N=0 placebo group	Placebo: 3%, 20 U: 8%, 40 U: 5%	N=1 insulin group	-	-	N=2 insulin group and N=0 placebo group
Rush	-	-	-	Placebo: 7%, 20 U: 3%, 40 U: 3%	-	-	-	
Changes in balance, extreme sensitivity to touch and general loss of interest	-	-	-	-	-	-	N=1	
Musculoskeletal injury/pain	-	-	-	-	-	-	-	N=1 insulin group and N=0 placebo group

Fig. 1

